Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 28;10(6):236.
doi: 10.3390/jcdd10060236.

Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality-A Comprehensive Review

Francesco Piccirillo  1   2 , Paola Liporace  1   2 , Annunziata Nusca  1   2 , Vincenzo Nafisio  1   2 , Andrea Corlianò  1   2 , Francesca Magarò  1   2 , Raffaele Antonelli Incalzi  1   3 , Gian Paolo Ussia  1   2 , Francesco Grigioni  1   2
Affiliations
Review

Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality-A Comprehensive Review

Francesco Piccirillo et al. J Cardiovasc Dev Dis. .

Abstract

Patients with cardiovascular disease (CVD) and chronic kidney disease (CKD) show high rates of cardiorenal outcomes. In addition, the progression towards renal failure and cardiovascular events rises as CKD worsens. Several studies suggest that the activation of the mineralocorticoid receptor (MR) induces cardiac and renal injury, including inflammation and fibrosis. Finerenone is a novel, nonsteroidal, selective MR antagonist (MRA) which has demonstrated anti-inflammatory and anti-fibrotic effects in pre-clinical studies. Moreover, two large trials (FIDELIO-DKD and FIGARO-DKD) investigated the renal and cardiovascular outcomes in patients with mild to severe CKD in type 2 diabetes which received finerenone. On these bases, this comprehensive review aims to summarize the current knowledge regarding finerenone and its effects on CKD and the cardiovascular system, emphasizing its role in modifying cardiorenal outcomes.

Keywords: cardiovascular disease; chronic kidney disease; finerenone; mineralocorticoid receptor; mineralocorticoid receptor antagonist; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Correlation between chronic kidney disease and cardiovascular disease.
Figure 2
Figure 2
Biochemical differences between the steroidal mineralocorticoid receptor antagonists and finerenone. CKD = chronic kidney disease; MRAs = mineralocorticoid receptor antagonists.
See this image and copyright information in PMC

References

    1. Ter Maaten J.M., Damman K., Verhaar M.C., Paulus W.J., Duncker D.J., Cheng C., van Heerebeek L., Hillege H.L., Lam C.S.P., Navis G., et al. Connecting heart failure with preserved ejection fraction and renal dysfunction: The role of endothelial dysfunction and inflammation. Eur. J. Heart Fail. 2016;18:588–598. doi: 10.1002/ejhf.497. - DOI - PubMed
    1. van der Pol A., van Gilst W.H., Voors A., van der Meer P. Treating oxidative stress in heart failure: Past, present and future. Eur. J. Heart Fail. 2019;21:425–435. doi: 10.1002/ejhf.1320. - DOI - PMC - PubMed
    1. Manjunath G., Tighiouart H., Ibrahim H., MacLeod B., Salem D.N., Griffith J.L., Coresh J., Levey A.S., Sarnak M.J. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J. Am. Coll. Cardiol. 2003;41:47–55. doi: 10.1016/S0735-1097(02)02663-3. - DOI - PubMed
    1. Vallianou N.G., Mitesh S., Gkogkou A., Geladari E. Chronic Kidney Disease and Cardiovascular Disease: Is there Any Relationship? Curr. Cardiol. Rev. 2019;15:55–63. doi: 10.2174/1573403X14666180711124825. - DOI - PMC - PubMed
    1. McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Böhm M., Burri H., Butler J., Čelutkienė J., Chioncel O., et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2021;42:3599–3726. doi: 10.1093/eurheartj/ehab368. - DOI - PubMed

LinkOut - more resources